<SEC-DOCUMENT>0001958244-24-002817.txt : 20240624
<SEC-HEADER>0001958244-24-002817.hdr.sgml : 20240624
<ACCEPTANCE-DATETIME>20240624173933
ACCESSION NUMBER:		0001958244-24-002817
CONFORMED SUBMISSION TYPE:	144
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20240624
DATE AS OF CHANGE:		20240624

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			4D Molecular Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001650648
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				473506994
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	001-39782
		FILM NUMBER:		241065536

	BUSINESS ADDRESS:	
		STREET 1:		5858 HORTON STREET #455
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
		BUSINESS PHONE:		5105052680

	MAIL ADDRESS:	
		STREET 1:		5858 HORTON STREET #455
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	4D Molecular Therapeutics Inc.
		DATE OF NAME CHANGE:	20200506

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	4D Molecular Therapeutics Inc
		DATE OF NAME CHANGE:	20150811

REPORTING-OWNER:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Kirn David
		CENTRAL INDEX KEY:			0001834021
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		144

	MAIL ADDRESS:	
		STREET 1:		C/O 4D MOLECULAR THERAPEUTICS INC.
		STREET 2:		5858 HORTON STREET #455
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
</SEC-HEADER>
<DOCUMENT>
<TYPE>144
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><ns2:edgarSubmission xmlns:com="http://www.sec.gov/edgar/common" xmlns:ns2="http://www.sec.gov/edgar/ownership">
    <ns2:headerData>
        <ns2:submissionType>144</ns2:submissionType>
        <ns2:filerInfo>
            <ns2:filer>
                <ns2:filerCredentials>
                    <ns2:cik>0001834021</ns2:cik>
                    <ns2:ccc>XXXXXXXX</ns2:ccc>
                </ns2:filerCredentials>
            </ns2:filer>
            <ns2:liveTestFlag>LIVE</ns2:liveTestFlag>



        </ns2:filerInfo>
    </ns2:headerData>
    <ns2:formData>
        <ns2:issuerInfo>
            <ns2:issuerCik>0001650648</ns2:issuerCik>
            <ns2:issuerName>4D Molecular Therapeutics, Inc.</ns2:issuerName>
            <ns2:secFileNumber>001-39782</ns2:secFileNumber>
            <ns2:issuerAddress>
                <com:street1>5858 Horton Street</com:street1>
                <com:street2>Suite 455</com:street2>
                <com:city>Emeryville</com:city>
                <com:stateOrCountry>CA</com:stateOrCountry>
                <com:zipCode>94608</com:zipCode>
            </ns2:issuerAddress>
            <ns2:issuerContactPhone>1-510-505-2680</ns2:issuerContactPhone>
            <ns2:nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>David Kirn</ns2:nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
            <ns2:relationshipsToIssuer>
                <ns2:relationshipToIssuer>Officer</ns2:relationshipToIssuer>
            </ns2:relationshipsToIssuer>
        </ns2:issuerInfo>
        <ns2:securitiesInformation>
            <ns2:securitiesClassTitle>Class A Common</ns2:securitiesClassTitle>
            <ns2:brokerOrMarketmakerDetails>
                <ns2:name>Goldman Sachs &amp; Co. LLC</ns2:name>
                <ns2:address>
                    <com:street1>200 West Street</com:street1>
                    <com:city>New York</com:city>
                    <com:stateOrCountry>NY</com:stateOrCountry>
                    <com:zipCode>10282</com:zipCode>
                </ns2:address>
            </ns2:brokerOrMarketmakerDetails>
            <ns2:noOfUnitsSold>12930</ns2:noOfUnitsSold>
            <ns2:aggregateMarketValue>300622.5</ns2:aggregateMarketValue>
            <ns2:noOfUnitsOutstanding>51703412</ns2:noOfUnitsOutstanding>
            <ns2:approxSaleDate>06/24/2024</ns2:approxSaleDate>
            <ns2:securitiesExchangeName>NASD</ns2:securitiesExchangeName>
        </ns2:securitiesInformation>
        <ns2:securitiesToBeSold>
            <ns2:securitiesClassTitle>Class A Common</ns2:securitiesClassTitle>
            <ns2:acquiredDate>02/10/2022</ns2:acquiredDate>
            <ns2:natureOfAcquisitionTransaction>Acquired as compensation -- Stock Options</ns2:natureOfAcquisitionTransaction>
            <ns2:nameOfPersonfromWhomAcquired>Issuer</ns2:nameOfPersonfromWhomAcquired>
            <ns2:isGiftTransaction>N</ns2:isGiftTransaction>
            <ns2:amountOfSecuritiesAcquired>4625</ns2:amountOfSecuritiesAcquired>
            <ns2:paymentDate>06/24/2024</ns2:paymentDate>
            <ns2:natureOfPayment>Compensation -- Cashless exercise / same-day sale</ns2:natureOfPayment>
        </ns2:securitiesToBeSold>
        <ns2:securitiesToBeSold>
            <ns2:securitiesClassTitle>Class A Common</ns2:securitiesClassTitle>
            <ns2:acquiredDate>12/11/2023</ns2:acquiredDate>
            <ns2:natureOfAcquisitionTransaction>Acquired as compensation -- Stock Options</ns2:natureOfAcquisitionTransaction>
            <ns2:nameOfPersonfromWhomAcquired>Issuer</ns2:nameOfPersonfromWhomAcquired>
            <ns2:isGiftTransaction>N</ns2:isGiftTransaction>
            <ns2:amountOfSecuritiesAcquired>8305</ns2:amountOfSecuritiesAcquired>
            <ns2:paymentDate>06/24/2024</ns2:paymentDate>
            <ns2:natureOfPayment>Compensation -- Cashless exercise / same-day sale</ns2:natureOfPayment>
        </ns2:securitiesToBeSold>
        <ns2:nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</ns2:nothingToReportFlagOnSecuritiesSoldInPast3Months>
        <ns2:remarks>The sales of shares set forth herein are made in connection with a selling plan dated 3/21/2024, that is intended to comply with Rule 10b5-1(c).</ns2:remarks>
        <ns2:noticeSignature>
            <ns2:noticeDate>06/24/2024</ns2:noticeDate>
            <ns2:planAdoptionDates>
                <ns2:planAdoptionDate>03/21/2024</ns2:planAdoptionDate>
            </ns2:planAdoptionDates>
            <ns2:signature>Goldman Sachs &amp; Co. LLC on behalf of David Kirn</ns2:signature>
        </ns2:noticeSignature>
    </ns2:formData>
</ns2:edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
